Alan S. Tall, MD

Board Certifications: 
Internal Medicine

Overview

Academic Appointments

  • Tilden-Weger-Bieler Professor of Medicine
  • Professor of Physiology & Cellular Biophysics

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Credentials & Experience

Education & Training

  • University of Sydney, Faculty of Medicine (Australia)
  • Internship: Royal Prince Alfred Hospital
  • Residency: Boston Medical Center
  • Fellowship: Boston Medical Center

Board Certifications

  • Internal Medicine

Honors & Awards

1996 - 1998, Tenure Review Advisory Committee, Columbia; University
1993 - 1995, Committee on Appointments and Promotions, Columbia University, Chairman, 1995.

Research

The laboratory is carrying out research on the molecular mechanisms responsible for human diseases. The approach is to use molecular, genomic and cellular approaches to investigate basic aspects of the pathogenesis of atherosclerosis. A major focus is on molecular mechanisms of cellular cholesterol efflux, mediated by the interaction of extracellular apoA-I with the lipid transporter ABCA1. We are carrying out studies on the transcriptional regulation of ABCA1 gene expression, and regulation of the degradation of ABCA1 protein. This has led to the elucidation of a class of transcription factors (LXRs) that co-ordinately regulate cellular cholesterol efflux and reverse cholesterol transport.

Grants

MECHANISMS LINKING LNK GENETIC VARIATION TO ATHEROTHROMBOSIS (Federal Gov)

Jul 1 2017 - May 31 2021

HDL-MEDIATED CHOLESTEROL EFFLUX AND PLAQUE INFLAMMATION IN MESA (Federal Gov)

Jul 1 2016 - Apr 30 2020

ANALYZE BIOLOGICAL SAMPLES OF GENES, RNA, PROTEINS AND METABOLITES FROM PFIZER''S BIOBANK AND TISSUE BANK - PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690... (P&S Industry Clinical Trial)

May 23 2014 - May 23 2019

TTC39B IN METABOLISM (Federal Gov)

Nov 4 2014 - Oct 31 2018

MECHANISMS OF ATHEROGENESIS IN INSULIN RESISTANCE (Federal Gov)

Feb 1 2013 - Jan 31 2018

HYPERINSULINEMIA, MTOR ACTIVITY AND PLASMA LIPOPROTEINS (Federal Gov)

Apr 16 2012 - Mar 31 2016

HIGH DENSITY LIPOPROTEIN DYSFUNTION IN DEVELOPMENT OF CARDIOVASCULAR DISEASE AND A THERAPEUTIC TARGET (Private)

Oct 1 2010 - Sep 30 2015

ABCG1 AND ENDOTHELIAL FUNCTION (Federal Gov)

Jan 3 2011 - Dec 31 2014

THE ROLE OF THE IL-3 RECEPTOR COMMON B-SUBUNIT IN REGULATING HSPC PROLIFERATION, MONOCYTOSIS AND ATHEROSCLEROSIS (Private)

Jul 1 2012 - Jun 30 2014

STUDY OF THE ROLE OF EXENATIDE IN ATHEROSCLEROTIC PLAQUE STABILIZATION IN A MURINE MODEL (Private)

Feb 10 2010 - Feb 9 2014

USE OF PEGYLATED HUMAN APOA-1 FOR THE TREATMENT OF ATHEROSCL EROSIS-PHASE 1 (Private)

Dec 22 2009 - Dec 21 2013

MACROPHAGE FOAM CELLS, CATHEPSINS AND CHOLESTEROL EFFLUX (Federal Gov)

Jul 1 1978 - Jul 31 2012

THE ROLE OF ABCA1 IN ATHEROSCLEROSIS REGRESSION (Private)

Jul 1 2010 - Jun 30 2012

THE ROLE OF MYELOID CELL PROLIFERATION IN ATHEROGENESIS IN M ICE WITH DEFICIENCY ON ABC TRANSPORTERS IN BONE MARROW CELLS (Private)

Jul 1 2009 - Jun 30 2012

ROLE OF ENDOTHELIAL CHOLESTEROL TRANSPORTERS IN ATHEROGENESI S (Private)

Jul 1 2009 - Jun 30 2011

NEW GENES AND PATHWAYS INVOLVED IN ATHEROSCLEROSIS PROJECT (Federal Gov)

Jul 1 1997 - Mar 31 2011

HDL AND ENDOTHELIAL FUNCTION: STUDIES WITH HDL FROM ANACETRA PIBTREATED SUBJECTS (Private)

Dec 8 2008 - Dec 7 2009

MEASURE ANTI-INFLAMATORY PROPERITIES OF HDL IN SUBJECT TREAT ED WITH MERCK CETP INHIBITOR (Private)

Jun 13 2007 - Jun 12 2008

STUDY TO EXAMINE THE EFFECTS OF PHARMACEUTICAL AGENTS ON HDL FUNCTION (Private)

Nov 1 2006 - Oct 31 2007

GENETICS OF ATHEROSCLEROSIS--FROM MICE TO HUMANS (Private)

Jul 1 2003 - Jun 30 2007

Selected Publications

  • Wang N, Chen W, Linsel-Nitschke P, Martinez L, Agerholm-Larsen B, Silver DL, Tall AR. (2003 ) A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest. 111(1):99-107
  • Tall AR. (2002 ) Exercise to reduce cardiovascular risk - how much is enough? N Engl J Med. 347(19):1522-4
  • Tall AR, Costet P, Wang N. (2002 ) Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest. 110(7):899-904
  • Jiang, XC, Qin, S, Qiao, C, Kawano, K, Lin, M, Xiao, X, Tall, AR. (2001 ) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7(7):847-52
  • Luo Y, Liang CP, Tall AR. (2001 ) The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J Biol Chem. Jul 6;:. 276(27):24767-73
  • Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, Pleskac N, Liang C-P, Barlow C, Dansky H, Breslow JL, Tall AR. (2001 ) Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. PNAS 98(14):7946-51